Contineum Therapeutics appoints Timothy Watkins as CMO and Head of Development

Contineum Therapeutics, Inc.

Dr. Watkins appointed Chief Medical Officer effective April 28, 2025, succeeding Dr. Stephen Huhn.
He previously served as VP and Therapeutic Area Head for Inflammation at Gilead Sciences.
Company plans to start Phase 2 proof-of-concept trial in IPF in H2 2025.
Received time-based option for 260,000 shares vesting over 42 months and performance-based option for 26,000 shares.
Grants are inducement awards under Nasdaq Listing Rule 5635(c)(4).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.